Yahoo! Finance: SVNT News

Friday Options Update: SVNT, JBLU, ROST, RVSN, MRVL, RYL, ARIA, WLP (at Seeking Alpha)

Fri, 18 Dec 2009 20:48:44 Etc/GMT

Savient To Present at the 28th Annual JP Morgan Healthcare Conference (PR Newswire)

Thu, 10 Dec 2009 21:05:00 Etc/GMT

Savient Pharmaceuticals, Inc. today announced that Paul Hamelin, R.Ph., President of Savient will present at the JP Morgan Healthcare Conference on Monday, January 11, 2010 at 2:30 p.m.

SAVIENT PHARMACEUTICALS INC Financials (EDGAR Online Financials)

Fri, 13 Nov 2009 14:05:46 Etc/GMT

SAVIENT PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements a (EDGAR Online)

Mon, 9 Nov 2009 20:11:30 Etc/GMT

New Star Analyst Rankings for Savient Pharmaceuticals Inc (StarMine)

Thu, 5 Nov 2009 14:29:25 Etc/GMT

Savient Pharmaceuticals Reports Third Quarter 2009 Financial Results (PR Newswire)

Thu, 5 Nov 2009 00:23:00 Etc/GMT

Savient Pharmaceuticals, Inc. today reported financial results for the three and nine months ended September 30, 2009, ending the quarter with $67.5 million in cash and short-term investments, a reduction of $11.1 million from December 31, 2008.

Q3 2009 Savient Pharmaceuticals, Inc. Earnings Release - After Market Close (CCBN)

Wed, 4 Nov 2009 12:07:29 Etc/GMT

Savient Pharmaceuticals to Hold Third Quarter 2009 Financial Results Conference Call on Thursday, November 5, 2009 (PR Newswire)

Wed, 28 Oct 2009 22:32:00 Etc/GMT

News) announced today that the company will release financial results for the third quarter 2009 following the close of the market on Wednesday, November 4, 2009.

Savient Pharmaceuticals to Present at the Oppenheimer 20th Annual Healthcare Conference (GlobeNewswire)

Tue, 27 Oct 2009 20:30:00 Etc/GMT

SAVIENT PHARMACEUTICALS INC Files SEC form 8-K/A, Costs Associated with Exit or Disposal Activities (EDGAR Online)

Thu, 22 Oct 2009 20:52:00 Etc/GMT

Wedbush Morgan Biotech Analyst Sees Access To Capital Increasing Again For Small Cap Firms (Wall Street Transcript)

Tue, 20 Oct 2009 15:00:00 Etc/GMT

67 WALL STREET, New York - October 20, 2009 - The Wall Street Transcript has just published its Biotechnology Report offering a timely review of the sector to serious investors and industry executives. This 70 page feature contains expert industry commentary through in-depth interviews with public company CEOs, Equity Analysts and Money Managers. The full issue is available by calling (212) 952-7433 or via The Wall Street Transcript Online.

SAVIENT PHARMACEUTICALS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits (EDGAR Online)

Thu, 15 Oct 2009 17:12:28 Etc/GMT

Savient Pharmaceuticals Announces Closing of Public Offering and Exercise of Over-Allotment Option (PR Newswire)

Thu, 15 Oct 2009 15:22:00 Etc/GMT

Savient Pharmaceuticals, Inc. announced today the closing of its previously announced underwritten public offering. Prior to closing, the underwriters exercised in full their option to purchase an additional 645,000 shares of common stock.

[$$] Russell 2000, S&P 600 Rise for Week (at The Wall Street Journal Online)

Sat, 10 Oct 2009 01:20:58 Etc/GMT

Savient Pharma recovers after analyst upgrade (AP)

Fri, 9 Oct 2009 19:53:48 Etc/GMT

Shares of Savient Pharmaceuticals Inc. rebounded Friday as an analyst for Oppenheimer and Co. raised his views on Savient and its chronic gout drug candidate Krystexxa.

SAVIENT PHARMACEUTICALS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits (EDGAR Online)

Fri, 9 Oct 2009 16:22:33 Etc/GMT

Savient Pharma expects $52.9M from stock offer (AP)

Fri, 9 Oct 2009 14:16:58 Etc/GMT

Savient Pharmaceuticals Inc. expects to raise $52.9 million through a stock sale. The company expanded a stock offering late Thursday, saying it will sell at least 4.3 million shares at $13.29 per share.

Savient Pharma upgraded by Oppenheimer (Briefing.com)

Fri, 9 Oct 2009 05:45:48 Etc/GMT

Savient Pharmaceuticals Prices Underwritten Offering of Common Stock (PR Newswire)

Thu, 8 Oct 2009 23:53:00 Etc/GMT

Savient Pharmaceuticals, Inc. announced today the pricing of an underwritten offering of 4,300,000 shares of its common stock at a price of $13.29 per share.

SAVIENT PHARMACEUTICALS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits (EDGAR Online)

Thu, 8 Oct 2009 20:14:51 Etc/GMT